Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVO756 in Chronic Inducible Urticaria
NCT06603220Phase 2Completed
- Sponsor
- Evommune
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of EVO756 in chronic inducible urticaria (CIndU) (2 arms), sponsored by Evommune. Primary endpoint: Safety and Tolerability at 6 weeks. Started Aug 2024; status: completed.
02
Drugs
EVO756
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT06603220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603220.